Tesamorelin: evidence, side effects and UK licensing explained
Get practical health advice and updates on Puri Pharmacy services straight to your inbox.
Tesamorelin has clinical evidence for a specific medical problem: excess abdominal fat in adults with HIV-associated lipodystrophy. That does not make it a general treatment for belly fat, bodybuilding or healthy ageing. Its US approval should not be presented as UK authorisation, and its proposed general wellness uses remain investigational.
- A medical indication is narrower than a marketing claim about fat loss.
- A reduction in visceral fat is not the same measurement as percentage body-weight loss.
- Relevant risks and monitoring requirements remain, even with a regulated medicine.
- Tesamorelin is prohibited in and out of competition under the 2026 WADA List.
Puri Pharmacy’s position: we do not sell, supply or prescribe tesamorelin. This is education, not an invitation to obtain it. We recognise that people may already be using research products and want them to seek advice without judgement. Some peptide medicines are licensed for specific indications; this does not validate unrelated products or uses.
What is tesamorelin?
Tesamorelin is an analogue of growth hormone-releasing hormone: a modified molecule that signals the pituitary gland to release growth hormone. That signalling pathway helps explain why researchers investigated it, but a plausible mechanism does not tell us who benefits. The European Medicines Agency’s assessment describes its development for HIV-related changes in abdominal fat.
It is useful to separate three questions. Can a substance alter a biological pathway? Does it improve a relevant outcome in a particular group? Do the benefits outweigh the harms for that use? A positive answer to the first question cannot answer the other two.
What is it approved for in the United States?
The March 2025 FDA prescribing information for Egrifta WR specifies reduction of excess abdominal fat in adults with HIV and lipodystrophy. It explicitly excludes weight-loss management and states that long-term cardiovascular safety has not been established.
The indication belongs to a defined regulated product and patient group. It does not turn a research-labelled vial into that medicine. Nor does approval in one country automatically establish authorisation in another. Reading only the words “FDA approved” omits the information most important to a patient: approved for whom, for what purpose and in which preparation?
What did the human trial actually measure?
In a 2007 randomised trial reported by Falutz and colleagues, 412 patients with HIV and abdominal fat accumulation received tesamorelin or placebo for 26 weeks. Visceral adipose tissue decreased by 15.2% in the treatment group and increased by 5.0% in the placebo group. Most participants were men. These findings concern abdominal fat in that population, not a 15.2% reduction in overall body weight.
Why visceral fat and body weight are different outcomes
Visceral fat is fat within the abdominal cavity around internal organs. Subcutaneous fat lies beneath the skin. Body weight also includes muscle, bone, water and other tissues. A percentage change in one compartment cannot be relabelled as the same percentage change in the whole body.
For example, a headline saying “15% fat reduction” leaves several questions unanswered. Which fat was measured? How was it measured? Over what period? Was the number a change from baseline or a difference compared with placebo? Did physical function, illness or quality of life improve? These questions are not technicalities; they change the meaning of the result.
The two trial percentages should also not be casually described as “20% weight loss”. Subtracting changes in an imaging outcome does not create a body-weight outcome. Before-and-after photographs are not a substitute for the trial’s measurement method.
Does that support tesamorelin for ordinary belly fat?
It does not establish that use. Someone without HIV-associated lipodystrophy is not necessarily comparable to the trial participants. The underlying condition, other treatments and balance of benefit and harm may differ. An intervention can have a useful medical role in one setting without being appropriate for people seeking cosmetic changes.
Nor is reducing a measurement automatically proof of fewer heart attacks, longer life or improved sporting performance. Those claims need their own evidence. A useful interpretation should state the outcome actually studied rather than substituting a more appealing outcome that was not established.
What happened to the European application?
The EMA records withdrawal of the Egrifta application in June 2012. At that time, its committee had unresolved concerns about identifying appropriate patients, the clinical meaning of the fat reduction and long-term safety. This is a historical European regulatory assessment, not proof of today’s UK product status by itself.
The important distinction is between evidence of an effect and a regulator’s assessment of the overall benefit–risk balance. Regulators can examine the same development programme yet reach different conclusions within their respective processes. Neither a US approval nor a withdrawn European application should be reduced to a slogan.
What are the side effects and contraindications?
The US label lists risks including raised IGF-1, fluid retention, joint discomfort, carpal tunnel symptoms, glucose intolerance or diabetes, allergic reactions and injection-site reactions. Contraindications include active malignancy, pregnancy, relevant disruption of the hypothalamic–pituitary system and known hypersensitivity. These are selected points, not a complete prescribing checklist. See the official product information.
That information should not be used to construct a self-screening test: “none of these applies, therefore it is safe for me”. It comes from a regulated treatment context. An unverified product adds separate questions about its identity, concentration and quality, while an unstudied purpose adds uncertainty about benefit.
People who are pregnant or breastfeeding, under 18, living with significant illness or taking other medicines should not use an online article to decide suitability. A history of cancer or pituitary disease requires particular clinical attention. Do not change prescribed medicines to accommodate a research product.
What blood tests matter?
The US prescribing information includes assessment of glucose and monitoring of IGF-1 within treatment. That is not a validated testing package for recreational use. FDA monitoring information.
A normal blood result cannot establish product authenticity or predict every adverse effect. Equally, a change in a marker is not automatically a reason to increase or decrease an experimental product. Testing needs a clinical question, an interpretation and a plan for acting on the result. “Monitor everything” is not a substitute for those steps.
Is tesamorelin licensed or legal in the UK?
It should not be presented as a licensed UK wellness or general weight-loss treatment. UK prescribing and supply questions need assessment under UK rules. The MHRA describes restricted supply of unlicensed medicines for individual clinical needs under Regulation 167 of the Human Medicines Regulations 2012. This is not general permission to market wellness products.
A research label also does not settle medicine status: MHRA assessment considers claims, presentation and properties. “Unlicensed” should not be simplified to “illegal in every possible circumstance”.
What should athletes know?
Tesamorelin is named under S2 growth hormone-releasing factors in the 2026 WADA Prohibited List. It is prohibited at all times. A prescription is not automatic sporting permission; follow UKAD’s medication-checking guidance.
A practical next step
If you have HIV and a concern about fat distribution, discuss it with your HIV clinical team. Do not alter antiretroviral treatment yourself. If your concern is general weight, fatigue or body composition, start with assessment of that concern rather than choosing a hormone intervention first.
- What condition is being assessed, rather than just which measurement is changing?
- Does the evidence involve people in my situation?
- Which established options address my actual concern?
- What would a test result change about my care?
- If I have already used a product, what information should I bring?
Bring a medicines list and, if relevant, the product label, source and timing of use. This helps a clinician interpret symptoms; it does not make the product suitable. Sudden throat or tongue swelling or breathing difficulty requires 999, as described in NHS anaphylaxis guidance.
Frequently asked questions
Is tesamorelin simply another name for growth hormone?
No. It acts on the pathway that stimulates release. That difference in mechanism does not prove a safer outcome for wellness use.
Can the trial result predict how much weight I would lose?
No. The headline result concerned visceral fat in a defined HIV population, not an individual weight-loss prediction.
Does a certificate of analysis make a vial equivalent to a licensed medicine?
No. A document about a sample does not establish the complete identity, manufacturing, storage and clinical evidence of a regulated finished medicine.
Can normal IGF-1 prove continued use is safe?
No single result can establish that. It also cannot demonstrate that the intended benefit is occurring.
Does Puri Pharmacy offer tesamorelin?
No. This article supports informed questions and appropriate clinical advice, not access to tesamorelin.
Key takeaways
- Keep the specific medical indication separate from general wellness claims.
- Read the trial outcome accurately: visceral fat is not total body weight.
- Foreign approval does not establish UK authorisation.
- Medical monitoring does not certify experimental self-use.
Evidence summary
This summary draws on the studies and official guidance linked above.
- What human evidence shows: There is human evidence and a specific US medical indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
- What is not established: A reduction in visceral fat is not the same percentage reduction in total body weight, and US approval does not establish UK authorisation.
- Main safety uncertainties: Glucose effects, IGF-1 changes and fluid retention require attention; an online preparation adds separate quality uncertainty.
- What would change the assessment: For a broader claim, relevant trials in that population measuring the claimed outcome and harms, plus current UK regulatory evidence.
Continue reading
- Examples of reading peptide claims
- UK licensing and prescribing explained
- Retatrutide: promising findings, safety and UK status
Follow Rahul’s peptide analysis
Subscribe to Puri Pharmacy’s health updates, including Rahul Puri’s explanations of peptide evidence, safety and UK regulation. This is an educational newsletter, not access to peptide treatment.
By subscribing, you agree to receive Puri Pharmacy’s health emails. Read our privacy policy.
Have a question about a claim? Use our contact form and include the article or study you want explained. Do not post personal health information in public comments. These articles provide education; Puri does not supply the experimental research peptides discussed here.
For symptoms or an individual treatment decision, seek appropriate clinical advice. For urgent symptoms, seek urgent medical care directly rather than waiting for a pharmacy reply.
